CYP cynata therapeutics limited

9.68%

17.0¢

All very wonderful and why we're in this business... So Smarty,...

First 29 Last

Share
Profile

Follow
Sector

35,472 Posts.

2863

22/09/18

18:12

Post #: 35775710
Share

Originally posted by smarty13 ↑

We all want a higher share price an I for one have other goals I need to achieve at Xmas an no I will have to sell shares to achieve so the higher the price the better for me

But I am extremely happy with the way we are heading and this why

We have shown fantastic lab results across multiple fields asthma, cardio vas etc

We have outstanding universities across the world utilising our cymerus platform for research

This all means if there was a takeover these factors will come into our price tag

We have a major insto on our books along with a top 200 in the world company Fuji

And the big one we haven’t yet set a true bench mark for the price of our product which I really like ! We didn’t really know how good our product is now we do ! Now we can come to the table with facts proof and demand what we want not ask our partners to float there money on a lab result like we had with Fuji (double digit royalties ??) we are now setup to offer stage 2 trials a proven product and a massive advantage to anyone who wants to be a leader in this field.
We have only just gotten to this point where we are in the controlling spot of any negotiation so give a few months fellas this is big dollars here no need to rush for a deal but ensure it’s the best deal even though personally I wish they would hurry up JMT

Expand

All very wonderful and why we're in this business...

So Smarty, what's holding things back?
Why are we 37c off all time highs?

Any insights?

Last edited by Sector: 22/09/18

CYP Price at posting: $1.21 Sentiment: Buy Disclosure: Held
6 Upvote

1 Great analysis

Reply

Top Stories

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

There are more pages in this discussion • 391 more messages in this thread...

First 29 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change 0.015(9.68%)		Mkt cap ! $38.41M

Open	High	Low	Value	Volume
15.5¢	17.0¢	15.5¢	$47.10K	289.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	23813	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.165
4	47240	0.155
4	161673	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.170	23813	3
0.175	55250	1
0.180	62619	3
0.185	35990	1
0.195	19300	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

All very wonderful and why we're in this business... So Smarty,...

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Australia’s gas crisis is here – and dying coal plants aren’t helping

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

All very wonderful and why we're in this business... So Smarty,...

Top Stories

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Australia’s gas crisis is here – and dying coal plants aren’t helping

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

'Not possible' to port renewable gas: ACCC takes AGN to court

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News